Table 2

Five-year results from entry into the BEVORDEX trial

DEX-implant
(46 eyes)
Bevacizumab
(42 eyes)
P value
BCVA at the end of trial (2 years)62.4 (14.6)65.9 (13)0.38
VA at 5 years, letters (CI)*58.5 (55.1 to 61.9)59.5 (57.4 to 63.6)0.51
Proportion of eyes who gained ≥10 letters from baseline to 5 years, n (%)*14 (30.4)14 (33.3)0.78
Mean change in vision from baseline, letters (CI)*1.8 (−1.6 to 5.3)2.7 (0.62 to 6.94)0.40
Mean CMT at end of study, µm (CI)*329 (265 to 452)358 (286 to 415)0.36
Mean CMT at 5 years, µm (CI)*327 (289 to 367)332 (293 to 371)0.87
Mean change in CMT (from baseline to 5 years), µm (CI)*−150 (−199 to −100)−173 (−232 to −121)0.23
Paired t-test (end of study to 5 years)0.870.81
  • *Last observation carried forward.

  • BCVA, best corrected visual acuity; CMT, central macular thickness; DEX, dexamethasone; VA, visual acuity (obtain from patient file).